Get started
Author

Nick R. Waldron

Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
2021 · Axel S. Merseburger, Nick Waldron, et al. · European Urology · 41
The effect of 1.5 T cardiac magnetic resonance on human circulating leucocytes
2017 · William R Critchley, Anna Reid, et al. · European Heart Journal · 9
PDF
Prostate cancer
2020 · Nick Waldron, Simon Chowdhury · Medicine · 8
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
2025 · Juan M. Jiménez-Vacas, Daniel Westaby, et al. · Nature Communications · 7
PDF
The Value of Cardiovascular Magnetic Resonance in Heart Transplant Patients
2015 · Anna B. Reid, Nick Waldron, et al. · Current Cardiology Reports · 5
Current management of advanced bladder cancer
2017 · Nick Waldron, Thomas Young, et al. · Trends in Urology & Men s Health · 4
PDF
Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities
2026 · Nick R. Waldron, Diogo Silva, et al. · British Journal of Cancer · 3
PDF
Prostate cancer
2022 · Nick Waldron, Simon Chowdhury, et al. · Medicine · 3
Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma
2022 · Nadia Hitchen, Nick R. Waldron, et al. · Asia-Pacific Journal of Clinical Oncology · 3
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al. · Clinical Cancer Research · 2
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
2025 · Daniel Westaby, Juan M. Jiménez-Vacas, et al. · iScience · 1
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Data from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Table 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Table 5 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplemental Tables 1-2 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Real-World Outcomes in Advanced Clear Cell Renal Cell Carcinoma: A Retrospective Analysis Comparing New Zealand and Australian Cohorts
2026 · William Harris, Sarah Shirley, et al. · JCO Global Oncology
Using a clinical deterioration scenario (video) as an approach for interprofessional learning
2020 · Kylie Russell, Heidi Waldron, et al. · Journal of Interprofessional Education & Practice
Efficacy of abiraterone or enzalutamide following docetaxel chemotherapy in the hormone-sensitive setting.
2018 · Nick Waldron, Thomas Young, et al. · Journal of Clinical Oncology
Primary resistance in docetaxel and androgen deprivation therapy in metastatic castrate sensitive prostate cancer patients.
2018 · Athanasios Pouptsis, Styliani Germanou, et al. · Journal of Clinical Oncology
009 The effect of cardiac magnetic resonance on human circulating leukocytes
2017 · William Critchley, Anna Reid, et al. · Abstracts
PDF
Works count: 25
Citation count: 86
H-index: 5
I10-index: 1
Year
Topic
Type